Eos Energy stock falls after Fuzzy Panda issues short report
Investing.com - Quince Therapeutics Inc. (NASDAQ:QNCX), a clinical-stage biotech with a market capitalization of $87.55 million, maintained its Market Outperform rating and $8.00 price target from JMP Securities following publication of pharmacokinetic modeling data for its eDSP therapy. According to InvestingPro data, analyst targets for QNCX range from $4 to $10, suggesting significant upside potential from current levels.
The publication in the Journal of the American Society for Clinical Pharmacology and Therapeutics provides additional validation for eDSP’s mechanism in the ongoing Phase 3 NEAT trial. The therapy uses the AIDE platform to encapsulate and deliver dexamethasone, designed to release approximately 40% of the total dose in the first 24 hours followed by slow diffusion over one month. InvestingPro analysis shows the company maintains a FAIR financial health score, with more cash than debt on its balance sheet, though it’s currently unprofitable.
JMP highlighted that eDSP maintains plasma concentrations below thresholds associated with steroid-related adverse events, addressing a key limitation of traditional corticosteroids. The firm noted that three patients treated with eDSP for over 13 years in the Phase 2 open-label extension showed no evidence of typical steroid-related side effects.
The pharmacokinetic analysis demonstrated that eDSP maintained low, sustained dexamethasone concentrations for 20-30 days without accumulation, even at high doses. JMP emphasized that the observed and simulated profiles in the 6-10 years age group were consistent.
Data from the Phase 3 NEAT trial remains on track for the first quarter of 2026, with JMP expressing confidence in potential success based on the trial’s focus on the high eDSP dose, primary analysis in 6-9 year olds, and the FDA’s special protocol assessment for a more selective primary endpoint. JMP assigns a 60% probability of success for eDSP in Ataxia-Telangiectasia with potential peak sales of approximately $800 million. While the company’s stock has shown impressive momentum with a 108.63% return over the past year, InvestingPro data indicates rapid cash burn remains a key consideration for investors.
In other recent news, Quince Therapeutics announced the publication of a study in CPT: Pharmacometrics & Systems Pharmacology, highlighting positive pharmacokinetic data for its Phase 3 lead asset, eDSP. This treatment, aimed at pediatric patients with Ataxia-Telangiectasia and healthy adults, encapsulates dexamethasone sodium phosphate in the patient’s red blood cells. Citizens JMP recently lowered its price target for Quince Therapeutics to $8, down from $9, while maintaining a Market Outperform rating. The firm expressed confidence in the company’s management and the ongoing NEAT trial for eDSP, citing the high dose’s effectiveness observed in previous trials. Meanwhile, JMP Securities initiated coverage of Quince Therapeutics with a Market Outperform rating and set a $9 price target, based on a risk-adjusted, discounted cash flow analysis of the company’s pipeline. Additionally, Quince Therapeutics expanded its Scientific Advisory Board with the appointment of Dr. Hassan Abolhassani, an immunology expert from the Karolinska Institutet. These developments reflect the company’s ongoing efforts in advancing its rare disease treatments and strengthening its advisory team.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.